Generative Artificial Intelligence (AI) In Drug Discovery Market Expansion 2024-2033: Growth Drivers and Dynamics

The generative artificial intelligence (ai) in drug discovery global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Generative Artificial Intelligence (AI) In Drug Discovery Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size -
The generative AI in drug discovery market size has grown exponentially in recent years. It will grow from $0.15 billion in 2023 to $0.19 billion in 2024 at a compound annual growth rate (CAGR) of 30.6%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, development of new drug discoveries and clinical trials, supporting AI integration into healthcare and drug development, growing biotech industries and increasing governmental support.

The generative AI in drug discovery market size is expected to see exponential growth in the next few years. It will grow to $0.57 billion in 2028 at a compound annual growth rate (CAGR) of 30.7%. The growth in the forecast period can be attributed to demand for cost-effective drug discovery drives adoption of generative AI, growing collaborations among market players, increasing computational power, integration of generative AI with other emerging technologies and rapid drug development. Major trends in the forecast period include advanced technologies, integration of generative AI with experimental biology, high-throughput screening for accelerated drug discovery pipelines, development of AI-driven platforms for drug repurposing and rising adoption of cloud-based AI solutions for collaborative drug discovery efforts.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Scope Of Generative Artificial Intelligence (AI) In Drug Discovery Market
The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Generative Artificial Intelligence (AI) In Drug Discovery Market Overview

Market Drivers -
The rising number of clinical trials is expected to propel the growth of generative AI in the drug discovery market. Clinical trials involve human volunteers and assess the safety and effectiveness of new medical treatments or procedures, aiming to gather scientific data on their suitability for human use. The rising number of clinical trials is primarily attributed to advancements in medical research, increased disease burden, regulatory changes, globalization of clinical research, patient advocacy and awareness, industry competition, technological advancements, and funding opportunities. Clinical trial data fuels generative AI models, expediting drug discovery by predicting interactions and designing compounds. This synergy enables personalized medicine, optimizes treatment efficacy, improves patient outcomes, and revolutionizes the pharmaceutical landscape. For instance, according to ClinicalTrials.gov, a US-based clinical trial registry, by the end of 2023, there were 477,234 clinical trials registered globally, marking an increase from the 437,512 trials registered in 2022. Therefore, the rising number of clinical trials is driving the growth of generative AI in the drug discovery market.

Market Trends -
Major companies operating in the generative AI in the drug discovery market are developing advanced AI-powered tools to accelerate drug discovery processes. AI-powered tools accelerate drug development by streamlining drug discovery, design, and clinical trials through predictive analytics and machine learning. They enhance efficiency in target identification and compound screening such as virtual screening using AI, preclinical development, regulatory compliance, and manufacturing processes. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, introduced two innovative AI-driven solutions. These solutions, the Target and Lead Identification Suite and the Multiomics Suite are designed to improve drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite helps researchers understand amino acid functions and predict protein structures, while the Multiomics Suite speeds up the analysis and understanding of genomic data, simplifying the development of personalized treatments.

The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users

Get an inside scoop of the generative artificial intelligence (ai) in drug discovery market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

Regional Insights -
North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are  Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc. , DeepMatter Group Limited, Variational AI Inc

Table of Contents
1. Executive Summary
2. Generative Artificial Intelligence (AI) In Drug Discovery Market Report Structure
3. Generative Artificial Intelligence (AI) In Drug Discovery Market Trends And Strategies
4. Generative Artificial Intelligence (AI) In Drug Discovery Market – Macro Economic Scenario
5. Generative Artificial Intelligence (AI) In Drug Discovery Market Size And Growth
…..
27. Generative Artificial Intelligence (AI) In Drug Discovery Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix